medigraphic.com
Colegio de Medicina Interna de México.

2006, Number 5

<< Back Next >>

Med Int Mex 2006; 22 (5)

Tendency of resistance to ciprofloxacin in bacteriemias due to Escherichia coli

Ayala GJJ, Chávez MG, Ríos MHA, Velarde PPA, Arzola GCY, Guajardo LCE

Language: Spanish
References: 24
Page: 386-390
PDF size: 238.31 Kb.


ABSTRACT

Background: Quinolone-resistant Escherichia coli strains are being isolated from blood with increasing frequency.
Objectives: To describe the trend in ciprofloxacin resistant E. coli bacteremia over a 15 years period, and to compare the epidemiological, clinical, risk factors and outcome of quinolone-resistant E. coli bacteremic patients with those due to quinolone-susceptible E. coli that occurred in the last seven years.
Material and methods: All E. coli-positive blood cultures collected by the laboratory of microbiology from January 1st of 1990 to December 31st of 2004 were analyzed. Retrospectively we studied all E. coli bacteremic patients from the last seven years; data collected included demographic characteristics, underlying diseases, source, antimicrobial therapy and outcome, and we compare quinolone-resistant E. coli bacteremic patients with those with quinolone-susceptible E. coli.
Results: Ciprofloxacin resistance reached 53%. We studied 50 E. coli bacteremic patients; isolates were more frequent from women, older than 65 years, without underlying diseases, the majority were considered non nosocomial. In 26 patients (52%) quinolone-resistant E. coli was isolated; no significantly factors associated with the development of quinolone-resistant E. coli bacteremia were found.
Conclusion: The number of E. coli isolates in blood resistant to ciprofloxacin is growing quickly. The epidemiological characteristics of quinolone-resistant E. coli bacteremia and quinolone-susceptible E. coli are the same. A rational use of antibiotics, principally quinolones, is necessary.


REFERENCES

  1. Diekema DJ, Pfaller MA, Jones RN, Doern GV, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY antimicrobial surveillance program, 1997. Clin Infect Dis 1999;29:595-607.

  2. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.

  3. Schaeffer AJ. The expanding role of fluoroquinolones. Dis Mon 2003; 49:129-47.

  4. D´Antonio D, Piccolomini R, Iacone A, Fioritoni G, et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with hematological malignancies. J Antimicrob Chemother 1994;33:837-44.

  5. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacina with ciprofloxacin. The GIMENA Infection Program. Gruppo Italiano Malattie Ematologiche de´ll Adulto. Ann Intern Med 1991;115:7-12.

  6. Pena C, Albareda JM, Pallares R, Pujol M, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.

  7. Ena J, Lopez-Perezagua MM, Martínez-Peinado C, Cia-Barrio MA, Ruiz-López I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-7.

  8. Performance standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards 2004; 124:1-159.

  9. Aquiar JM, Chacon J, Canton R, Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother 1992;29:349-50.

  10. Perez-Trallero E, Urbieta M, Jimenez D, García-Arenzana JM, Cilla G. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 1993;12:349-51.

  11. Livermore DM, Nichols T, Lamagni TL, Potz N, Reynolds R, Duckworth G. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. J Antimicrob Chemother 2003;52:1040-2.

  12. Livermore DM, James D, Reacher M, Graham C, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8:473-8.

  13. Karlowsky JA, Jomes ME, Draghi DC, Thornsberry C, et. al. Prevalence of antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob 2004; 3:7.

  14. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43:2736-41.

  15. Nema S, Premchandani P, Asolkar MV, Chitnis DS. Emerging bacterial drug resistance in hospital practice. Indian J Med Sci 1997; 51:275-80.

  16. Kato-Maeda M, Bautista-Alvarez A, Ramos-Hinojosa A, Ponce-de-Leon A, et. al. Tendencia en el incremento de la resistencia antimicrobiana en organismos causantes de bacteremia en un hospital de tercer nivel: 1995-2000. Rev Invest Clin 2003; 55:600-5.

  17. Javaloyas M, Garcia-Somoza D, Guidol F. Bacteremia due to Eschericha coli: epidemiological analysis and sensitivity to antibiotics in a county hospital. Med Clin (Barc) 2003;120:125-7.

  18. Olesen B, Kolmos HJ, Orskov F, Orskov I, Gottschau A. Bacteremia due to Escherichia coli in a Danish university hospital, 1986-1990. Scand J Infect Dis 1995; 27:253-7.

  19. Vazquez F, Mendoza MC, Viejo G, Mendez FJ. Survey of Escherichia coli septicemia over a six-year period. Eur J Clin Microbiol Infect Dis 1992;11:110-7.

  20. Gransden WR, Eykyn SJ, Phillips I, Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev Infect Dis 1990; 12:1008-18.

  21. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Eschericha coli and Klebsiella pneumoniae infections: The role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41:923-9.

  22. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Guidol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have recived prophylactic norfloxacin. Clin Infect Dis 1995; 20:557-60.

  23. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001;33:48-53.

  24. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J; Spanish members of EARSS. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg Infect Dis 2005;11:546-53.




2020     |     www.medigraphic.com